Skip to Content

MT 100

Treatment for Migraine

FDA Sets August 4, 2005 for Advisory Committee Meeting to Consider Tardive Dyskinesia Risk with MT 100

CHAPEL HILL, N.C., June 29, 2005 - Pozen Inc. (NASDAQ: POZN), a pharmaceutical company focused primarily on products for the treatment of migraine, acute and chronic pain and other pain-related conditions, announced today that the U.S. Food and Drug Administration (FDA) has set August 4, 2005 as the date for the meeting of the FDA's Peripheral and Central Nervous System Drugs Advisory Committee. The Advisory Committee is expected to review the potential risk of the occurrence of an involuntary neurological movement disorder known as tardive dyskinesia with the use of Pozen's product candidate MT 100 for the treatment of migraine.

About Pozen
Pozen is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, Pozen has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. Pozen is also exploring the development of product candidates in other pain-related therapeutic areas.

Posted: June 2005

Related Articles

MT 100 (metoclopramide hydrochloride and naproxen sodium) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.